Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel

@article{Jiang2015ClinicalPA,
  title={Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel},
  author={Xi-Ling Jiang and Snehal Samant and Lawrence J. Lesko and Stephan Schmidt},
  journal={Clinical Pharmacokinetics},
  year={2015},
  volume={54},
  pages={147-166}
}
Acute coronary syndromes (ACS) remain life-threatening disorders, which are associated with high morbidity and mortality. Dual antiplatelet therapy with aspirin and clopidogrel has been shown to reduce cardiovascular events in patients with ACS. However, there is substantial inter-individual variability in the response to clopidogrel treatment, in addition to prolonged recovery of platelet reactivity as a result of irreversible binding to P2Y12 receptors. This high inter-individual variability… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults.

  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS

References

Publications referenced by this paper.
SHOWING 1-10 OF 200 REFERENCES

Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel.

  • Drug metabolism and disposition: the biological fate of chemicals
  • 2009
VIEW 13 EXCERPTS
HIGHLY INFLUENTIAL

Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation.

  • The Journal of pharmacology and experimental therapeutics
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

The CYP2C19*17 variant is not independently associated with clopidogrel response.

  • Journal of thrombosis and haemostasis : JTH
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL